M Receptor Antagonist Crystals With Safer Scalable Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypropyl)-1-azabicyclo[2,2,2]octylonium bromide (Compound I) are inefficient, costly, and hazardous due to the use of toxic reagents like dimethyl sulfate and dimethyl sulfide, and require column chromatography, making them unsuitable for industrial production.
Innovation Solution
A novel method involving the use of sodium borohydride to reduce cyclopentyl mandelic acid, followed by esterification and quaternization steps, allows for the production of two crystalline forms of Compound I (Type-A and Type-B) with reduced residual solvents and impurities, using safer solvents and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If dimethyl sulfate and dimethyl sulfide are used to prepare the intermediate 1-phenyl-1-cyclopentyl oxirane, then the synthesis can proceed, but highly toxic and genotoxic reagents are required, creating safety and environmental hazards
Solution Approach 1:
The patent replaces expensive, toxic, and hazardous reagents (dimethyl sulfate, dimethyl sulfide, and large amounts of NaH) with safer, more environmentally friendly alternatives. The new method uses readily available reagents that are less hazardous, eliminating the need for specialized safety handling while maintaining synthesis efficiency and product quality.
2Manufacturing precision
If column chromatography is used to separate the free base of (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-azabicyclo[2,2,2]octane, then separation can be achieved, but the utilization rate of (R)-3-quinuclidinol drops to 50%, increasing production costs
Solution Approach 1:
The patent changes the separation approach from column chromatography (which causes significant material loss) to a method based on pH control and selective precipitation. By adjusting the pH and using appropriate solvents, the free base can be separated with high purity while maintaining over 90% utilization rate of the expensive (R)-3-quinuclidinol starting material.
3Ease of manufacture
If ether is used to precipitate Compound I in the final step, then solid raw pharmaceutical material can be obtained, but ether is a high-risk solvent not suitable for modern industrial production
Solution Approach 1:
The patent replaces ether, a highly flammable and hazardous solvent, with safer alternative solvents that are suitable for industrial production. The new method achieves the same product isolation and crystallization效果 using solvents with lower safety risks, eliminating the need for specialized fire safety precautions while maintaining production efficiency.
4Quantity of substance
If the traditional synthesis method is used, then Compound I can be produced, but the process is complex, costly, and unsuitable for industrial production at scale
Solution Approach 1:
The patent segments the synthesis process into distinct, optimized steps with clear intermediates, allowing each step to be independently controlled and optimized for industrial scale-up. The method eliminates complex purification steps like column chromatography and replaces them with simpler, more scalable operations such as filtration and crystallization, thereby improving overall productivity and industrial applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new method results in high-purity Compound I crystals with improved stability and safety, suitable for industrial production, and reduces production costs by enhancing the utilization rate of raw materials.
Implementation Method 1
reducing cyclopentyl mandelic acid or cyclopentyl mandelate... with sodium borohydride to obtain racemic compounds 2-hydroxy-2-cyclopentyl-2-phenylethanol
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides novel crystals of a quaternary ammonium salt structure compound, i.e., (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypropyl)-1-azabicyclo[2,2,2]octylonium bromide (Compound I). A Type-A crystal of Compound I displays diffraction peaks at the following diffraction angles 2Θ in a X-ray powder diffraction pattern thereof 5.7 ± 0.2 degrees, 12.9 ± 0.2 degrees, 16.7 ± 0.2 degrees, 18.0 ± 0.2 degrees, 19.5 ± 0.2 degrees, 21.1 ± 0.2 degrees, 22.3 ± 0.2 degrees and 23.3 ± 0.2 degrees. A Type-B crystal of Compound I displays diffraction peaks at the following diffraction angles 20 in a X-ray powder diffraction pattern thereof: 5.2 ± 0.2 degrees, 15.8 ± 0.2 degrees, 16.9 ± 0.2 degrees, 17.7 ± 0.2 degrees, 19.5 ± 0.2 degrees, 20.2 ± 0.2 degrees and 22.1 ± 0.2 degrees. The present application also relates to a new method for preparing Compound I and applications of the two novel crystals in the field of medicine.